XML 31 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Common Stock
Treasury Stock
Additional Paid in Capital
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid in Capital
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Other Comprehensive Income
Cumulative Effect, Period of Adoption, Adjustment
Total
Balance at beginning of period at Dec. 31, 2017 $ 1   $ 213 $ 6,933 $ (213) $ (104,556)     $ (97,622)
Balance at beginning of period (in shares) at Dec. 31, 2017 5,690,083                
Increase (Decrease) in Stockholders’ Equity                  
Repurchase of convertible preferred stock           (425)     (425)
Repurchase of common stock   $ (884)       (321)     (1,205)
Repurchase of common stock (in shares) (589,321)                
Non-cash contribution       414         414
Stock option exercise       65         65
Stock option exercises (in shares) 54,645                
Stock-based compensation       2,997         2,997
Net income           661     661
Balance at end of period at Dec. 31, 2018 $ 1 (884)   10,622   (104,854)     (95,115)
Balance at end of period (in shares) at Dec. 31, 2018 5,155,407                
Increase (Decrease) in Stockholders’ Equity                  
Repurchase of common stock   (125)       (60)     (185)
Repurchase of common stock (in shares) (26,659)                
Stock option exercise       6,536         6,536
Stock option exercises (in shares) 6,490,059                
Stock-based compensation       5,061         5,061
Conversion of convertible preferred stock to common stock upon initial public offering $ 7     106,230         106,237
Conversion of convertible preferred stock to common stock upon initial public offering (in shares) 65,428,088                
Conversion of convertible preferred stock warrants to common stock warrants upon initial public offering       22,765         22,765
Warrant exercise       62         62
Warrant exercise (in shares) 441,307                
Issuance of Common Stock in connection with initial public offering, net of issuance costs of $5.9 million and $3.7 million in offering costs       77,479         77,479
Net income           (8,569)     (8,569)
Balance at end of period at Dec. 31, 2019 $ 8 (1,009)   228,755 $ (1,169) (113,483)   $ (1,169) $ 114,271
Balance at end of period (in shares) at Dec. 31, 2019 84,188,202               84,188,202
Increase (Decrease) in Stockholders’ Equity                  
Issuance of employee equity awards, net of shares withheld $ 1     (5,451)         $ (5,450)
Issuance of employee equity awards, net of shares withheld (in shares) 2,688,273                
Stock option exercises (in shares)                 2,979,700
Stock-based compensation       (12,821)         $ (12,821)
Reduction in initial public offering costs       (14)         (14)
Warrant exercise       0         0
Warrant exercise (in shares) 177,854                
Other comprehensive income             $ 1   1
Net income           46,459     46,459
Balance at end of period at Dec. 31, 2020 $ 9 $ (1,009)   $ 236,139   $ (68,193) $ 1   $ 166,947
Balance at end of period (in shares) at Dec. 31, 2020 87,054,329               87,054,329